Lynparza Copay Card and Patient Assistance Programs

If you're struggling to afford Lynparza, there's hope. The Lynparza copay card can help reduce your out-of-pocket costs.

The copay card can cover up to $26,000 in annual medication costs. This can be a huge relief for those who are facing financial burdens due to treatment expenses.

To be eligible for the copay card, you must have a valid prescription for Lynparza and be a US resident.

The LYNPARZA Co-pay Savings Program is designed to help eligible patients with out-of-pocket costs.

Eligible patients may pay as little as $0 per month for LYNPARZA. This is a significant benefit, especially for those with commercial insurance.

The program is available to commercially insured patients, and there are no income requirements to participate.

You can enroll in the program by visiting AstraZenecaSpecialtySavings.com or calling AstraZeneca Access 360 at 1-844-ASK-A360(1-844-275-2360).

The program covers the cost of the drug, but does not cover costs for office visits or any other associated costs.

To be eligible, patients must have been prescribed LYNPARZA, be covered by commercial insurance, and be a resident of the United States or Puerto Rico.

Here are the specific requirements for eligibility:

If you're wondering who can apply for the LYNPARZA Co-pay Savings Program, the answer is patients who are covered by commercial insurance and their insurance does not cover the full cost of their prescription. This is a key requirement for eligibility.

To be eligible, you must also be a resident of the United States or Puerto Rico. This program is not available to everyone, so it's essential to check your eligibility before applying.

Here are the specific eligibility criteria:

The LYNPARZA Co-pay Savings Program is designed to help eligible patients with out-of-pocket costs.

Eligible patients may pay as little as $0 per month for LYNPARZA, with no income requirements to participate in the program.

There are no income requirements to participate in the program, however other restrictions may apply.

To find out more about the program and eligibility requirements, visit AZPatientSupport.com or AstraZenecaSpecialtySavings.com.

Eligible patients may be commercially insured and have been prescribed LYNPARZA.

To enroll in the Co-pay Savings Program, visit MyAccess360.com and select the appropriate medication from the drop-down menu.

Here are some key facts about the LYNPARZA Co-pay Savings Program:

The LYNPARZA Co-pay Savings Program can help eligible commercially insured patients with their out-of-pocket costs.

Independent patient assistance foundations may also be available to provide assistance with co-pay, transportation, premium, patient education, and other types of support.

To find out more about independent patient assistance foundations, visit https://www.astrazeneca-us.com/medicines/Affordability.html or call an Access 360 representative at 1-844-ASK-A360 (1-844-275-2360).

LYNPARZA is a prescription medicine used to treat adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited or acquired abnormal BRCA gene.

To be eligible for LYNPARZA, your healthcare provider will perform a test to ensure it's right for you.

LYNPARZA is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy.

LYNPARZA is taken by mouth 2 times a day with or without food, and each dose should be taken about 12 hours apart.

To take LYNPARZA correctly, you should swallow the tablets whole and not chew, crush, dissolve, or divide them.

If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time, and do not take an extra dose to make up for the missed one.

Here's a quick summary of how to take LYNPARZA:

LYNPARZA is used for maintenance treatment in adult patients with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy.

The treatment is specifically for patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A companion diagnostic is required for therapy selection, as it is FDA-approved for LYNPARZA.